
Spectrum Pharmaceuticals SPPI
Quarterly report 2023-Q1
added 05-11-2023
Spectrum Pharmaceuticals DPO Ratio 2011-2026 | SPPI
Annual DPO Ratio Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.05 K | - | - | - | 613 | 260 | 310 | 352 | 121 | 163 | 269 | 106 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 K | 106 | 360 |
Quarterly DPO Ratio Spectrum Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.29 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.29 K | 2.29 K | 2.29 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Verastem
VSTM
|
1.26 K | $ 5.04 | -4.73 % | $ 349 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
182 | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Avid Bioservices
CDMO
|
62.3 | - | - | $ 789 M | ||
|
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
35.1 | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
193 | $ 1.05 | -3.67 % | $ 21.5 M | ||
|
Summit Therapeutics
SMMT
|
84.9 K | $ 16.58 | -3.94 % | $ 12.4 B | ||
|
AbbVie
ABBV
|
65.5 | $ 209.4 | -0.83 % | $ 370 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
55 | $ 317.36 | -3.29 % | $ 41.6 B | ||
|
Aytu BioScience
AYTU
|
186 | $ 2.6 | -2.8 % | $ 16.3 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.29 | -3.6 % | $ 822 M |